Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
暂无分享,去创建一个
R. D. du Bois | S. Nathan | A. Wells | M. Glassberg | W. Bradford | L. Lancaster | I. Glaspole | D. Valeyre | T. King | U. Costabel | D. Lederer | J. Swigris | P. Noble | R. Fishman | C. Albera | C. Pereira | E. Fagan | Zhengning Lin | Kenneth F Glasscock